Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx is a biopharmaceutical company that focuses on developing and commercializing first-in-class medicines that meet unmet medical needs. Its Tenapanor product, marketed as IBSRELA and XPHOZAH, targets patients with specific gastrointestinal disorders. Despite a recent setback in reimbursement headwinds and a change in chief commercial officer, Ardelyx remains on solid footing to execute its current plan. With a strong pipeline, potential for continued prescription data growth, and initiatives to overcome access barriers, Ardelyx's $1 billion peak net sales goal seems achievable. However, the company still faces typical industry risks, including unexpected outcomes from clinical trials and regulatory uncertainty.

Bears say

Ardelyx is facing potential challenges with its commercial execution and competition from other players in the market, leading to a topline miss and revised guidance for its flagship product, Ibsrela. In addition, while the company has strong momentum with its other product, Xphozah, market dynamics and competition may affect its long-term success. Despite potential for growth in the future, the uncertain timeline for reaching key milestones and the need for increased investment in marketing and sales activities could negatively impact the company's financials and ultimately its stock price.

Ardelyx (ARDX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.